Antipodean Advisors’s Exact Sciences EXAS Stock Holding History

Antipodean Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,000	Closed	-$354K	–	14
2019 Q2	$354K	Buy	+3,000	New	+$302K	0.43%	11
2018 Q4	–	Sell	-54,000	Closed	-$4.26M	–	9
2018 Q3	$4.26M	Sell	54,000 -179,000	-77%	-$11.7M	5.28%	6
2018 Q2	$13.9M	Sell	233,000 -3,346	-1%	-$180K	17.56%	3
2018 Q1	$9.53M	Sell	236,346 -341,000	-59%	-$16.6M	10.54%	3
2017 Q4	$30.3M	Hold	577,346	–	–	24.63%	1
2017 Q3	$27.2M	Buy	577,346 +101,000	+21%	+$4.07M	22.96%	1
2017 Q2	$16.8M	Buy	476,346 +107,000	+29%	+$3.3M	9.48%	6
2017 Q1	$8.72M	Buy	369,346 +117,400	+47%	+$2.33M	4.26%	9
2016 Q4	$3.37M	Sell	251,946 -500,000	-66%	-$8.07M	1.35%	17
2016 Q3	$14M	Buy	+751,946	New	+$13.3M	6.91%	6
2016 Q1	–	Sell	-695,007	Closed	-$6.42M	–	20
2015 Q4	$6.42M	Buy	+695,007	New	+$6.46M	0.94%	14

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Antipodean Advisors's EXAS Position: Q3 2019 in Review

Antipodean Advisors sold out of Exact Sciences (EXAS) in Q3 2019, closing a stake of 3,000 shares — an estimated $354K sold.

Antipodean Advisors first reported a position in EXAS in Q4 2015 and held it in 11 quarters. The position peaked at $30.3M in Q4 2017. 475 funds tracked by Wall St. Rank hold EXAS as of Q3 2019.

Antipodean Advisors reported no remaining Exact Sciences position as of Q3 2019 after selling out during the quarter.
Antipodean Advisors sold 3,000 Exact Sciences shares in Q3 2019, an estimated $354K.
Antipodean Advisors first reported a position in Exact Sciences in Q4 2015 and held it in 11 quarters.
Antipodean Advisors's Exact Sciences position peaked at $30.3M in Q4 2017.
475 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2019.

Based on Antipodean Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.